VNS depression CPT
This article was originally published in The Gray Sheet
American Medical Association CPT Editorial Panel approves codes for vagusnerve stimulation (VNS) therapy for treatment-resistantdepression, Cyberonics confirms. The Houston firm recently obtained FDA approval for its VNS Therapy for this indication (1"The Gray Sheet" July 25, 2005, p. 17). The codes become effective Jan. 1...
You may also be interested in...
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.